Beijing Kangchuanglian Biopharmaceutical Technology Research

Beijing Kangchuanglian Biopharmaceutical Technology Research (Kangchuanglian) is the core innovative R&D subsidiary of the CSPC Pharmaceutical Group, one of China's largest pharmaceutical companies. Based in the Daxing Biomedical Industry Base in Beijing, the company focuses on the discovery and early-stage development of novel therapeutics across modalities including small molecules, biologics, and nucleic acids. Kangchuanglian leverages advanced proprietary platforms such as AI-driven drug design, a LiquidGel long-acting sustained-release delivery system, and mRNA nanotechnology. The company has achieved significant international recognition through high-value out-licensing deals, most notably a 2026 partnership with AstraZeneca valued at up to $18.5 billion for its once-monthly GLP-1/GIP agonist SYH2082 and other metabolic assets. Additionally, its MAT2A inhibitor SYH2039 was licensed globally to BeiGene, highlighting the company's capability to deliver high-potential clinical candidates for synthetic lethal oncology targets.